The IBD SmartSelect Composite Rating for Collegium Pharmaceutical rose from 90 to 97 Monday.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The new rating is a sign the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria.
Collegium Pharmaceutical is currently forming a cup without handle, with a 42.29 buy point. See if the stock can break out in heavy trade at least 40% above average.
One weak spot is the company's 75 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
In Q2, the company posted 4% EPS growth. Top line growth increased 29%, up from 23% in the prior report. That marks five consecutive reports with rising growth.
Collegium Pharmaceutical earns the No. 2 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
